Report Overview

The Australia Pyruvate Kinase Deficiency Disease Therapeutics Market size stood at around USD xx billion in 2020 and is projected to reach USD xx billion by 2028, exhibiting a CAGR of xx% during the forecast period.

Pyruvate Kinase (PK) Deficiency is an inherited and genetic disorder that affects the red blood cells (RBCs) which is responsible for carrying the oxygen to the body tissue. This condition is also known as Haemolytic Anaemia which is characterized by the broke down of red blood cells prematurely resulting in decreased units of RBCs in body. The complications for the PK can be from mild to severe and sometimes the patient does not show any symptoms. The main cause for PK deficiency is autosomal recessive trait that is the child gets the disease from their family members. The frequency of PKD is not precisely defined, but it has an estimated prevalence of 3 to 8 per 1000000.



Market Growth Drivers

Increase in Pyruvate Kinase (PK) Deficiency in the population and high diagnostic rates are some of the driver factors for the Pyruvate Kinase (PK) Deficiency market growth. Increase in patient population suffering from thegenetic diseaseis also one of the factors for the Pyruvate Kinase (PK) Deficiency market growth.

Market Restraints

Huge financial burden coupled with lack of skilled professionals are the factors that hinder the growth of the Pyruvate Kinase (PK) Deficiency market.